Tower Research Capital (TRC)’s Loncar China BioPharma ETF CHNA Stock Holding History

Tower Research Capital (TRC)’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	–	–	6499
2023 Q1	$0	Hold	2	–	–	﹤0.01%	6548
2022 Q4	$0	Buy	+2	New	+$33	﹤0.01%	6625
2020 Q4	–	Sell	-4	Closed	–	–	5488
2020 Q3	$0	Buy	+4	New	+$126	﹤0.01%	5193
2019 Q4	–	Sell	-44	Closed	-$1K	–	4599
2019 Q3	$1K	Buy	+44	New	+$983	﹤0.01%	3964

Other funds holding CHNA

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s CHNA Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Loncar China BioPharma ETF (CHNA) in Q2 2023, closing a stake of 2 shares.

Tower Research Capital (TRC) first reported a position in CHNA in Q3 2019 and held it in 4 quarters. The position peaked at $1K in Q3 2019. 4 funds tracked by Wall St. Rank hold CHNA as of Q2 2023.

Tower Research Capital (TRC) reported no remaining Loncar China BioPharma ETF position as of Q2 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 2 Loncar China BioPharma ETF shares in Q2 2023.
Tower Research Capital (TRC) first reported a position in Loncar China BioPharma ETF in Q3 2019 and held it in 4 quarters.
Tower Research Capital (TRC)'s Loncar China BioPharma ETF position peaked at $1K in Q3 2019.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.